Zacks Research Upgrades Vogenx (NASDAQ:VOGX) to Hold

Vogenx (NASDAQ:VOGX) was upgraded by research analysts at Zacks Research to a “hold” rating in a report released on Monday, Zacks reports.

A number of other equities analysts also recently issued reports on the company. Wall Street Zen upgraded Vogenx to a “hold” rating in a research report on Saturday, August 22nd. JonesTrading began coverage on shares of Vogenx in a report on Tuesday, September 1st. They set a “buy” rating and a $55.00 price target for the company. Finally, WBB Securities began coverage on shares of Vogenx in a research report on Wednesday, September 2nd. They issued a “speculative buy” rating and a $42.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat, Vogenx has an average rating of “Buy” and an average target price of $48.50.

Vogenx Stock Up 10.5%

NASDAQ VOGX opened at $24.32 on Monday. Vogenx has a twelve month low of $12.95 and a twelve month high of $38.41.

Vogenx (NASDAQ:VOGX) last announced its earnings results on Thursday, September 17th. The company reported ($0.07) EPS for the quarter. On average, sell-side analysts predict that Vogenx will post -0.61 EPS for the current year.

About Vogenx

Vogenx, Inc was a biotechnology company focused on the discovery and development of novel therapies for inflammatory and metabolic diseases. Its research activities centered on small-molecule drug candidates intended to address conditions associated with chronic inflammation and immune-system dysfunction.

The company’s lead investigational compound was VGX-1027, an orally administered candidate studied for its potential anti-inflammatory and immunomodulatory effects. Publicly available information describes research applications involving diseases such as diabetes and other inflammatory disorders, although the company’s development programs were not established as widely marketed commercial products.

Vogenx was based in the United States and operated as a development-stage biopharmaceutical company.